Translational stroke research of the combination of thrombolysis and antioxidant therapy - PubMed (original) (raw)
Translational stroke research of the combination of thrombolysis and antioxidant therapy
Sergio Amaro et al. Stroke. 2011 May.
Abstract
Stroke is an enormous public health problem with an imperative need for more effective therapy. Recombinant tissue plasminogen activator is the only licensed drug for acute stroke, but its efficacy may be limited by the toxicity of the compound and by reperfusion injury. The coadministration of neuroprotective drugs could augment the value of thrombolytic therapy, but the evidence in support of this approach is scarce. The use of the free radical trapping NXY-059, either with or without recombinant tissue plasminogen activator, was not successful in Phase III studies. However, these results could reflect its weak antioxidant capacity, poor blood-brain barrier penetration, and lack of synergism with recombinant tissue plasminogen activator as well as the overly broad treatment window used in the reported trials. This article contends that further translational research should explore newer antioxidant drugs in combination with thrombolytic agents, but only if the combination yields additive or synergistic effects in preclinical thromboembolic models or in biomarker-assisted Phase II studies. Edaravone and novel nitrones endowed with a better pharmacokinetic profile or multitarget and thrombolytic activity are discussed as well as the latest research data on uric acid, a strong endogenous antioxidant in blood that is early consumed after acute stroke. The coadministration of uric acid and recombinant tissue plasminogen activator has shown to provide synergistic neuroprotection in experimental thromboembolic models and to lessen several biomarkers of oxidative stress in patients with acute stroke. The clinical efficacy of uric acid is currently under investigation in a Phase III trial that follows current recommendations of also evaluating surrogate biomarkers of treatment effects.
Comment in
- Letter by Nardi and Milia regarding article, "translational stroke research of the combination of thrombolysis and antioxidant therapy".
Nardi K, Milia P. Nardi K, et al. Stroke. 2011 Sep;42(9):e547. doi: 10.1161/STROKEAHA.111.624460. Epub 2011 Aug 4. Stroke. 2011. PMID: 21817142 No abstract available.
Similar articles
- Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Green AR, Ashwood T. Green AR, et al. Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):109-18. doi: 10.2174/1568007053544156. Curr Drug Targets CNS Neurol Disord. 2005. PMID: 15857295 Review. - Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.
Lapchak PA, Song D, Wei J, Zivin JA. Lapchak PA, et al. Exp Neurol. 2004 Aug;188(2):279-85. doi: 10.1016/j.expneurol.2004.02.005. Exp Neurol. 2004. PMID: 15246827 - NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized?
Fisher M. Fisher M. Stroke. 2006 Oct;37(10):2651-2. doi: 10.1161/01.STR.0000242800.29490.a1. Epub 2006 Aug 31. Stroke. 2006. PMID: 16946143 No abstract available. - Plasminogen activation and thrombolysis for ischemic stroke.
Medcalf RL, Davis SM. Medcalf RL, et al. Int J Stroke. 2012 Jul;7(5):419-25. doi: 10.1111/j.1747-4949.2012.00783.x. Epub 2012 Mar 30. Int J Stroke. 2012. PMID: 22463085 Review.
Cited by
- The neurovascular unit and combination treatment strategies for stroke.
Zhang L, Zhang ZG, Chopp M. Zhang L, et al. Trends Pharmacol Sci. 2012 Aug;33(8):415-22. doi: 10.1016/j.tips.2012.04.006. Epub 2012 May 16. Trends Pharmacol Sci. 2012. PMID: 22595494 Free PMC article. Review. - Association between Pretreatment Serum Uric Acid Levels and Progression of Newly Diagnosed Primary Angle-Closure Glaucoma: A Prospective Cohort Study.
Li S, Shao M, Cao W, Sun X. Li S, et al. Oxid Med Cell Longev. 2019 Feb 7;2019:7919836. doi: 10.1155/2019/7919836. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 30881597 Free PMC article. - Methylene blue protects astrocytes against glucose oxygen deprivation by improving cellular respiration.
Roy Choudhury G, Winters A, Rich RM, Ryou MG, Gryczynski Z, Yuan F, Yang SH, Liu R. Roy Choudhury G, et al. PLoS One. 2015 Apr 7;10(4):e0123096. doi: 10.1371/journal.pone.0123096. eCollection 2015. PLoS One. 2015. PMID: 25848957 Free PMC article. - The role of uric acid as a potential neuroprotectant in acute ischemic stroke: a review of literature.
Li R, Huang C, Chen J, Guo Y, Tan S. Li R, et al. Neurol Sci. 2015 Jul;36(7):1097-103. doi: 10.1007/s10072-015-2151-z. Epub 2015 Mar 13. Neurol Sci. 2015. PMID: 25772077 Review. - Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors.
Chen R, Lai UH, Zhu L, Singh A, Ahmed M, Forsyth NR. Chen R, et al. Front Cell Dev Biol. 2018 Oct 10;6:132. doi: 10.3389/fcell.2018.00132. eCollection 2018. Front Cell Dev Biol. 2018. PMID: 30364203 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical